MKLN1 and gastric cancer: Luo et al.37 reported a strong correlation between EIF3J-DT and the development of drug resistance in gastric cancer cells, while Chen et al.38 suggested MKLN1-AS as a therapeutic target for hepatocellular carcinoma (HCC).